The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity
Open accessAbstract
Background: Mutations in KRAS are a common oncogene driver detected in approximately 30% of non-squamous non-small cell lung cancer (NSCLC) cases, conferring a poor prognosis without effective targeted therapy. Immune checkpoint inhibitors against PD-1/ PD-L1 yield improved survival rates of KRAS-mutant NSCLC patients while changing the paradigm of cancer therapy. Yet, the underlying association between KRAS mutations and immune responses remains unclear.Methods: We performed an integrated analysis of the data from publicly available repositories and from clinical center cohorts to explore the association between KRAS mutation status and tumor immunity-associated features, including PD-L1 expression, CD8+ tumor-infiltrating lymphocytes (TILs) and tumor mutational burden (TMB). Three-pool analysis was performed to assess the efficacies of different PD-1/PD-L1 inhibitors regarding objective response rates (ORR), durable clinical benefit, and overall survival (OS) in NSCLC patients with or without KRAS mutations. In addition, a KRAS-mutant lung adenocarcinoma mouse model was established to estimate the relative efficacy of anti-PD-L1 monoclonal antibody (mAb) monotherapy or combination treatment with docetaxel versus docetaxel alone.Findings: Pool analysis of 23 public studies suggested that patients with KRAS mutations had increased PD-L1 expression (OR=1.87; 95% CI: 1.34-2.61; P=0.0002). The combined analysis of PD-L1 and CD8+ TIL in the immunostained group showed increased dual-positive (PD-L1+/TIL+) cells in the KRAS-mutant group (P=0.008), suggesting KRAS mutations induce an inflammatory phenotype. Additional data verified a prominently increased KRAS mutant-associated TMB (TCGA: P=0.0155; Broad database: P=0.0001), indicating KRAS mutations promote tumor immunogenicity in NSCLC. Further molecular analyses revealed that KRAS mutations caused various defects in cell cycle checkpoints and DNA damage response pathways. Two-pool analysis confirmed that PD-1/PD-L1 inhibitors resulted in better ORR (OR=1.51; 95% CI: 1.17-1.96; P=0.002) and improved OS compared with docetaxel chemotherapy (HR=0.64; 95% CI: 0.43-0.95; P=0.03) KRAS-mutant NSCLC patients. Finally, anti-PD-L1 mAb significantly reduced tumor growth compared with docetaxel in KRASG12C lung adenocarcinoma mice (P<0.001), while PD-L1 mAb combined with docetaxel did not promote an anti-tumor response.Interpretation: KRAS-mutant NSCLC patients show remarkable clinical benefit from anti-PD-1/PD-L1 immunotherapy. We also uncovered a complex relationship among KRAS mutations, inflammatory phenotypes, and tumor immunogenicity. Importantly, our findings demonstrate that PD-1/PD-L1 inhibitor-based monotherapy may be more effective in KRAS-mutant NSCLC patients.Funding: This work was mainly supported by CIFMS.Declaration of Interest: The authors declare that they have no competing interests.Ethical Approval: This study was approved by the Ethics Committee of CICAMS, and all participants provided written informed consent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Cited by
The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker
Jardim, D. L., Goodman, A., de Melo Gagliato, D., & Kurzrock, R. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.10.001 · Cited by 1,192
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127
Self-citationResistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 421
Immune modulatory effects of oncogenic KRAS in cancer
Hamarsheh, S., Groß, O., Brummer, T., & Zeiser, R. (2020) · Nature Communications · doi:10.1038/s41467-020-19288-6 · Cited by 387
Patient-derived xenograft (PDX) models, applications and challenges in cancer research
Abdolahi, S., Ghazvinian, Z., Muhammadnejad, S., Saleh, M., Asadzadeh Aghdaei, H., & Baghaei, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03405-8 · Cited by 326
Metadata
- Authors
- Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., Mao, S., Wang, Y., Feng, X., Sun, N., Wang, Y., & He, J.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 470
- Pages
- 95-105
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W2981114563
- Cited by
- 281
- References
- 51
- FWCI
- 12.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. https://app.cochat.ai/papers/10.1016/j.canlet.2019.10.027
- The paper
- Liu, C., Zheng, S., Jin, R., Wang, X., Wang, F., Zang, R., Xu, H., Lu, Z., Huang, J., Lei, Y., Mao, S., Wang, Y., Feng, X., Sun, N., Wang, Y., & He, J. (2020). The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Letters. https://doi.org/10.1016/j.canlet.2019.10.027
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.